Allspring Global Investments
ZVRA icon

Allspring Global Investments’s Zevra Therapeutics ZVRA Stock Holding History

Allspring Global Investments’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,706
Closed -$22.7K – 2782
2023
Q3 		$22.7K Buy
+4,706
New +$23.5K ﹤0.01% 2482
2022
Q2 		– Sell
-48
Closed – – 2964
2022
Q1 		$0 Buy
+48
New +$305 ﹤0.01% 3076

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $246M AUM 27.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments's ZVRA Position: Q4 2023 in Review

Allspring Global Investments sold out of Zevra Therapeutics (ZVRA) in Q4 2023, closing a stake of 4,706 shares — an estimated $22.7K sold.

Allspring Global Investments first reported a position in ZVRA in Q1 2022 and held it in 2 quarters. The position peaked at $22.7K in Q3 2023. 84 funds tracked by Wall St. Rank hold ZVRA as of Q4 2023.

  • Allspring Global Investments reported no remaining Zevra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 4,706 Zevra Therapeutics shares in Q4 2023, an estimated $22.7K.
  • Allspring Global Investments first reported a position in Zevra Therapeutics in Q1 2022 and held it in 2 quarters.
  • Allspring Global Investments's Zevra Therapeutics position peaked at $22.7K in Q3 2023.
  • 84 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.